Amy Parison
Fortuna: 48 503 $ al 30/06/2026
Fortuna: 48 503 $ al 30/06/2026
Amy Parison is currently Chief Financial Officer & Senior Vice President at Editas Medicine, Inc. since 2025.
Formerly, Ms. Parison was Corporate Controller at Rubius Therapeutics, Inc. from 2021 to 2022.
Education includes undergraduate and graduate degrees from Babson College.
| Empresa | Fecha | Número de acciones | Valoración | Fecha de valoración |
|---|---|---|---|---|
EDITAS MEDICINE, INC. 0,01 % | 03/06/2026 | 14.970 ( 0,01 % ) | 48 503 $ | 30/06/2026 |
| Empresas | Cargo | Inicio |
|---|---|---|
| EDITAS MEDICINE, INC. | Director Financiero/CFO | 28/03/2025 |
| Empresas | Cargo | Fin |
|---|---|---|
| RUBIUS THERAPEUTICS | Director de Operaciones | 01/08/2021 |
Activas
Inactivas
Empresas cotizadas
Empresas privadas
Relaciones de 1er grado
Empresas vinculadas al 1er grado
Hombre
Mujer
Administradores
Ejecutivos
| Empresas privadas | 3 |
|---|---|
Babson College
Babson College Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
Editas Medicine, Inc.
Editas Medicine, Inc. BiotechnologyHealth Technology Manufactures gene editing medicines | Health Technology |
Rubius Therapeutics, Inc.
Rubius Therapeutics, Inc. BiotechnologyHealth Technology Develops red cell therapeutics for cancer treatment | Health Technology |
Selecciona tu edición
Toda la información financiera adaptada al ámbito nacional.